NexGard

Afoxolaner, the active ingredient in NexGard, is a isoxazoline presented as a chewable tablet for oral use. It treats flea and tick infestations in dogs by delivering systemic ectoparasite control through a single monthly dose, offering convenient and rapid protection.

GNH USA supplies NexGard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for veterinary professionals seeking high‑quality antiparasitic solutions, ensuring compliance with regulatory standards and timely delivery across global markets for all customers.

NexGard (afoxolaner) is an isoxazoline ectoparasiticide used to control external parasites in dogs.

Flea infestation: eliminates adult fleas and prevents new infestations for up to one month. Tick infestation: kills attached ticks and prevents attachment of new ticks for up to one month. Canine ectoparasite control: provides broad‑spectrum protection against common external parasites in dogs.

Adverse reactions reported with NexGard are generally mild, but veterinary monitoring is advised.

Common Side Effects: - Mild gastrointestinal upset: occasional vomiting or soft stools. - Transient lethargy: temporary reduced activity. - Reduced appetite: brief decrease in food intake.

Serious or Rare Side Effects: - Seizures: rare neurologic events. - Anaphylactic reactions: severe allergic response. - Severe dermatitis: intense skin inflammation.

When using NexGard, consider the following precautions: - Dosage determination: based on the dog's weight as prescribed by a veterinarian. - Age restriction: not recommended for puppies under 8 weeks or under 2 kg. - Concurrent medications: review potential interactions with other ectoparasitic products. - Health status: use with caution in dogs with known neurological disorders. - Pregnancy and lactation: safety not established; consult veterinarian. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Potential drug interactions with NexGard should be evaluated by a veterinarian.

Major Interactions (Avoid): - Co‑administration with other isoxazoline products: risk of additive neurotoxicity. - Concurrent use of strong CYP3A4 inhibitors: may increase afoxolaner exposure. - Use with phenobarbital: potential antagonism.

Moderate Interactions (Monitor Closely): - Combination with other flea/tick preventatives: monitor for additive side effects. - Concurrent use of certain antihistamines: may increase sedation.